TENX INVESTOR ALERT: Tenax Therapeutics, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit Before December 28, 2026 Deadline

Robbins Geller Rudman & Dowd LLP issued an investor alert for Tenax Therapeutics, Inc. (NASDAQ: TENX), saying purchasers or acquirers of the company’s securities between Nov. 13, 2023 and Aug. 7, 2026 can seek appointment as lead plaintiff in a class action. The deadline to apply is Dec. 28, 2026. The lawsuit, Katz v. Tenax Therapeutics, Inc., No. 26-cv-01264 (M.D.N.C.), alleges violations of the Securities Exchange Act of 1934 by Tenax Therapeutics and certain current and former executives. The filing centers on TNX-103 (levosimendan), cleared by the FDA in Nov. 2023 for Phase 3 LEVEL trials, and on topline Phase 3 results reported Aug. 10, 2026 that allegedly missed primary and key secondary endpoints. The complaint claims the stock price dropped nearly 90%.